Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies

The Hematology Journal : the Official Journal of the European Haematology Association
Eva D RossmannAnders Osterborg

Abstract

Antigen expression intensity is becoming important for decision-making in relation to monoclonal antibody therapy. By quantifying CD20, CD22 and CD52 expression on chronic lymphocytic leukemia and normal (control) B cells, over time. The effect of Interleukin-4 therapy on CD20 antigen intensity on B-CLL cells in vivo was also determined. Lymphocytes were purified at weeks 0, 4 and 8 from five B-CLL patients, five healthy volunteers and seven B-CLL patients receiving IL-4 therapy. The number of antigen receptor sites was calculated in molecules of equivalent soluble fluorochrome using flow cytometry. The mean number of CD20 receptors at baseline was significantly lower on B-CLL cells compared to normal B cells (8160 vs 87 046; P<0.0001). Similar results were obtained for CD22 (8630 vs 27 647; P<0.01), but not for CD52 (371 303 vs 409 484; P = 0.54). When soluble fluorochrome values at weeks 4 and 8 were analysed as change in per cent from baseline (delta%), there was <10 delta% variability in CD20 expression on control B cells, but considerable variability (22.5-67.5 delta%) on B-CLL cells. Expression of CD22 in CLL and control B cells varied by <15 delta%. CD52 on CLL B cells showed slightly greater variability (+/-35 delta%) t...Continue Reading

Citations

Jun 10, 2006·Proceedings of the National Academy of Sciences of the United States of America·Mitchell HoIra Pastan
Mar 1, 2008·Biologics : Targets & Therapy·Marco MontilloEnrica Morra
Jul 10, 2010·OncoTargets and Therapy·Carmen Diana Schweighofer, Clemens-Martin Wendtner
Sep 19, 2003·Wiener klinische Wochenschrift·Ulrich Jäger
Oct 2, 2003·British Journal of Cancer·M V Blagosklonny
Jun 15, 2007·Cytometry. Part B, Clinical Cytometry·Eva D RossmannAnders Osterborg
Sep 19, 2008·Cancer·Grace K Dy, Alex A Adjei
Dec 22, 2012·Expert Opinion on Biological Therapy·Preetesh Jain, Susan O'Brien
Mar 8, 2005·Cancer Immunology, Immunotherapy : CII·Sonja OffnerBirgit Kohleisen
May 6, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Scott E JamesOliver W Press
Jun 2, 2012·Blood·Michael Hallek
Dec 11, 2019·Antibodies·Veena A Thomas, Joseph P Balthasar
Oct 20, 2004·The Journal of Biological Chemistry·Mitchell HoIra Pastan
Jul 27, 2007·Cancer Biotherapy & Radiopharmaceuticals·Cecilia HindorfGlenn D Flux
Oct 1, 2007·Current Hematologic Malignancy Reports·Eva Kimby
Apr 23, 2015·Expert Opinion on Investigational Drugs·Michele MerliFrancesco Passamonti
Feb 5, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Tadeusz Robak
Jan 30, 2010·Expert Opinion on Biological Therapy·Anders Osterborg
Jul 17, 2008·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Carlos E PedreiraUNKNOWN EuroFlow Consortium
Sep 21, 2011·Expert Review of Anticancer Therapy·Samantha Jaglowski, Jeffrey A Jones
Oct 31, 2014·Journal of Hematology & Oncology·Tejas SureshStefan K Barta
Dec 14, 2011·Hematology·Jon E Arnason, Jennifer R Brown
Sep 10, 2003·Seminars in Cancer Biology·Christoph von Schilling

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.